Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge
- If you are wondering whether Protagonist Therapeutics at around US$91.30 is starting to look expensive or still offers value, you are not alone.
- The stock has seen returns of 4.5% over the last 7 days, 11.6% over 30 days, 4.7% year to date, and 136.2% over the past year, with a 295.4% return over 3 years and 204.3% over 5 years.
- Recent interest in Protagonist Therapeutics has been shaped by ongoing developments in its drug pipeline and broader sector attention on biotechnology companies. These updates help frame why the share price has moved the way it has and why many investors are focusing more closely on the company.
- Even after these moves, Protagonist Therapeutics holds a valuation score of 3 out of 6. We will assess this using…
Source link
